AthleticsRuti Aga: Six-year ban, the methylprednisolone steroid mislabel and the arithmetic of a forged prescription

Ruti Aga: Six-year ban, the methylprednisolone steroid mislabel and the arithmetic of a forged prescription

मुख्य उत्तर: रुती आगा को एथलेटिक्स इंटीग्रिटी यूनिट ने छह साल का प्रतिबंध दिया: दो साल मेथिलप्रेडनिसोलोन की इन-कॉम्पिटिशन मौजूदगी के लिए, चार साल नकली पर्चे और दस्तावेज से छेड़छाड़ के लिए। मेथिलप्रेडनिसोलोन ग्लूकोकोर्टिकॉइड S9 है, एनाबॉलिक स्टेरॉयड नहीं; यह केवल प्रतियोगिता-अवधि में प्रतिबंधित है। मुख्य तथ्य: - AIU ने रुती आगा पर 10 सितंबर से छह साल का प्रतिबंध लगाया; अस्थायी निलंबन भी 10 सितंबर से था। - मार्च में चीन में हाफ मैराथन जीतने के बाद नमूना सकारात्मक आया; रेस का समय स्रोत में नहीं है। - दो साल पदार्थ-मौजूदगी और चार साल टैंपरिंग के जोड़ से कुल छह साल बने। - आगा ने घुटने की चोट बताई; पर्चा परिवार के सदस्य ने लिखा, जिसका मेडिकल पंजीकरण नहीं था और क्लिनिक अस्तित्व में नहीं था। - 2019 टोक्यो मैराथन खिताब और तीन वर्ल्ड मेजर दूसरे स्थान रिकॉर्ड में हैं; प्रतिबंध 2028 ओलंपिक चक्र को बाहर करता है। स्रोत: एथलेटिक्स इंटीग्रिटी यूनिट (AIU) का गुरुवार का बयान; प्रकाशन तिथि स्रोत में नहीं दी गई। संबंधित प्रश्नोत्तर: प्रश्न: क्या मेथिलप्रेडनिसोलोन स्टेरॉयड है? उत्तर: नहीं, यह S9 ग्लूकोकोर्टिकॉइड है और केवल इन-कॉम्पिटिशन प्रतिबंधित है। प्रश्न: छह साल का प्रतिबंध कैसे बना? उत्तर: दो साल पदार्थ-मौजूदगी और चार साल टैंपरिंग के जुड़ने से। प्रश्न: क्या 2019 टोक्यो खिताब रद्द हुआ? उत्तर: स्रोत में प्रतिबंध का दायरा नहीं दिया गया; 2019 खिताब स्वतः रद्द नहीं माना जा सकता।

On Thursday the Athletics Integrity Unit (AIU) issued its statement. Ruti Aga, a 32-year-old Ethiopian marathoner, was placed under a six-year ban. On the surface this is a doping case. In my ledger it opens with two numbers: two years and four years. Two years for presence of a substance, four years for tampering and a forged document. The sum is six. But the first technical question is this: methylprednisolone is not a prohibited steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and under the current List it is prohibited in-competition only, by injection, oral or rectal route. That correction changes the legal centre of the case.

Ruti Aga: Six-year ban, the methylprednisolone steroid mislabel and the arithmetic of a forged prescription

I was sitting with a split sheet in Pune when Aga won the 2026 Tokyo Marathon. That race placed her among elite marathoners. Three World Marathon Majors second places sit in her record. Now the AIU statement says a sample taken after she won a half marathon in China in March returned methylprednisolone. The mark from that race is not in the source. I do not know her time, her splits or the field strength. A number I have not reconciled is a number I do not print.

Ruti Aga: Six-year ban, the methylprednisolone steroid mislabel and the arithmetic of a forged prescription

Aga cited a knee injury. According to the report, the prescription was issued by a family member with no medical registration; the clinic named on the prescription did not exist; and the claim about an old prescription pad from a former workplace was disowned by the clinic. The AIU imposed two years for presence and four years for tampering. The ban was dated from 10 September; the provisional suspension had also run from 10 September. The statement does not give the year. This report rests on the AIU statement and public records; the March race mark, splits, field quality and the year of the ban are absent from the source.

Ruti Aga: Six-year ban, the methylprednisolone steroid mislabel and the arithmetic of a forged prescription

Start with the sanction arithmetic. Two years cover the presence violation. Methylprednisolone is a Specified Substance under S9, so two years is the standard period when intent is not proven. Four years cover tampering: misleading the investigation and producing a forged prescription. The sum matches the AIU’s standard sanction architecture. The 2 plus 4 also tells us the panel rejected the no-significant-fault mitigation. With genuine medical records, a real doctor, and a clear route and timing of injection, the case could have moved in another direction.

The media misdescription of methylprednisolone is the most important point in this case. Calling it an anabolic steroid is wrong. It is a glucocorticoid and is prohibited in-competition only. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. Out of competition, that treatment is legal. In road racing the in-competition window generally opens at 23:59 the day before the race. Had the injection been given before that window and documented properly, a defence existed. A Therapeutic Use Exemption was also a route. The forged prescription closed it.

The knee-injury explanation is mechanistically plausible. Knee inflammation and pain are common in marathoners. That plausibility is exactly what makes it dangerous. When an injury is real, the treatment paper trail is usually real too. Here three independent verifications failed: the clinic did not exist, the doctor was not registered, and the old-pad claim was disowned. This is not merely missing medical information; it is a broken documentary chain. Tampering becomes easier for the AIU to prove when three separate checks fail at once.

Add another line to the ledger: under standard AIU practice, the result and prize money from the competition where the sample was collected are annulled. The statement does not set out the disqualification scope. The 2026 Tokyo title is not automatically annulled unless earlier use is found. The real damage is forward-looking. A six-year ban at 32 makes a return at roughly 38. Ethiopian women’s marathon depth means even a 2:18–2:20 performer is not automatically selectable. The national-team door is effectively closed.

The real story is not performance but medical governance. The removal of a 32-year-old with no global championship medals does not measurably change Ethiopia’s medal capacity. What changes is the enforcement map. AIU road-running cases show a clustering of tampering charges. The investigative frontier is shifting from sample detection to document verification. Informal medical networks inside East African road-running entourages, the appearance-fee economy and the growing Chinese label-race calendar are linked. Where appearance fees are large, elite fields are deep; where elite fields are deep, AIU testing follows.

One convenient conclusion should be avoided. There is no proven endurance benefit from a glucocorticoid. It is easy to justify six years because a forged prescription was produced. The same sanction will also be read as an example of uneven enforcement. AIU rigour and the intensity of enforcement against East African road runners can both be true. In this case the hardest fact is not the substance but the paper. Had Aga explained timing and route with genuine records, the four-year tampering charge might never have attached. The defence was closed by the athlete’s own conduct.

Three things to watch next. First, whether the AIU publishes the scope of disqualification for the March race and its prize money. Second, whether the Ethiopian federation or a national agency takes separate action on document forgery. Third, whether an appeal reaches CAS; there is usually a window of about 21 days from the reasoned decision, but a document-based tampering finding is hard to overturn. My ledger says the effect will fall on the next generation of runners who move between Majors and Asian label races. Their agents, their physios and their prescriptions will now be examined at the same table.

I am a monk of small numbers. For me the six-year sum is not just a sanction; it shows how an injury, an informal treatment and a forged prescription can close a career. The question is not whether Ruti Aga is culpable; the AIU decision establishes that. The question is who audits the medical system in which a family member becomes a doctor and an old prescription pad becomes proof of treatment.

संबंधित खिलाड़ी